Professor Haitham Amal of the Hebrew University of Jerusalem has received a prestigious research grant from the Philadelphia Eagles Autism Foundation to develop new drugs for the treatment of Autism Spectrum Disorder (ASD).
Amal is the first researcher outside the United States to be awarded the $400,000 Eagles Autism Foundation Grant. He is one of only nine recipients selected by a panel of nationally recognized U.S. researchers.
“I am excited and honored to receive this significant award as the first global recipient,” says Amal, a professor at the Hebrew University School of Pharmacy, Institute for Drug Research, Faculty of Medicine. “This grant will enhance our research initiatives to develop ASD therapeutics that will help millions of children and families around the world.”
The grant is funding Amal’s groundbreaking research on the role of nitric oxide (NO) in ASD pathology. Amal published the first paper linking nitric oxide with ASD, which is a key step towards identifying a drug target for the disorder. NO is a multifunctional signaling molecule and a neurotransmitter that plays an important role in physiological and pathophysiological processes.
Recently, Amal co-founded and serves as the chief scientific officer at Point6 Bio Ltd, a computational biology company for the diagnosis and treatment of ASD. He is also partnering with a NASDAQ-traded U.S. pharmaceutical company to research and develop ASD drugs.
In his Laboratory for Neuromics, Cell Signaling and Translational Medicine, Amal leads a group of scientists whose goal is to discover therapeutics and biomarkers for ASD, Alzheimer’s disease and other brain disorders.
He has received many awards, including the Wolf Foundation’s prestigious Krill Prize; the Prusiner-Abramsky Research Award in Clinical and Basic Neuroscience; the Kaye Innovation Award; the Golda Meir Lectureship Award; and the Brettle Center for Research Award. He has also received numerous grants, including funding from the U.S. Department of Defense and the Israel Science Foundation.
Amal was listed among the “40 under 40” most promising people in Israel by TheMarker magazine, a major business publication.
Prior to joining Hebrew University, Amal was a senior postdoctoral fellow at the Massachusetts Institute of Technology, as well as an affiliate at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard University. In 2015, he earned his Ph.D. from the Technion-Israel Institute of Technology in nanotechnology and chemical engineering. Amal also holds an M.Sc. in Pharmacology from Tel Aviv University (2009) and a B.Sc. Pharmacy from Hebrew University (2007).
Click here to learn more about the Eagles Autism Foundation.
Be a part of our community
JNS serves as the central hub for a thriving community of readers who appreciate the invaluable context our coverage offers on Israel and their Jewish world.
Please join our community and help support our unique brand of Jewish journalism that makes sense.